Complement assays and uses thereof

Patent metadata

Field	Value
Publication number	US-9291622-B2
Application number	US-201013321522-A
Country	US
Kind code	B2
Filing date	May 21, 2010
Priority date	May 21, 2009
Publication date	Mar 22, 2016
Grant date	Mar 22, 2016

Abstract

The present invention provides methods for assessing complement activation and methods for assessing the ability of an agent or condition of interest to modulate complement activation. The present invention provides methods for assessing whether a subject has or is at increased risk of developing a complement-mediated disorder, e.g., age-related macular degeneration (AMD). Also provided are kits containing materials useful for performing the methods.

First claim

We claim:

1. A method of assessing complement activation in a sample, the method either comprising steps of:
(a) capturing intact C3 present in the sample or in a sub-sample thereof using an antibody that specifically binds to at least one epitope that is present in intact C3;
(b) quantifying intact C3 captured in step (a) using an antibody that specifically binds to at least one epitope of intact C3 and has a detectable label directly or indirectly linked thereto;
(c) capturing iC3b present in the sample or in a sub-sample thereof using an antibody that specifically binds to a neoepitope of iC3b;
(d) quantifying iC3b captured in step (c) using an antibody that specifically binds to at least one epitope of iC3b and has a detectable label directly or indirectly linked thereto; and
(e) calculating the ratio of iC3b to intact C3 using the results of (b) and (d) or comprising steps of:
(i) capturing intact C3 present in the sample or in a sub-sample thereof using an antibody that specifically binds to at least one epitope that is present in intact C3;
(ii) quantifying intact C3 captured in step (i) using an antibody that specifically binds to at least one epitope of intact C3 and has a detectable label directly or indirectly linked thereto;
(iii) capturing total C3 present in the sample or in a sub-sample thereof using an antibody that binds to total C3, wherein the antibody specifically binds to at least one epitope that is present in total C3;
(iv) quantifying total C3 captured in step (iii) using an antibody that specifically binds to at least one epitope of C3c or C3d and has a detectable label directly or indirectly linked thereto; and
(v) calculating the relative concentration of intact C3 and total C3 in the sample using the results of (ii) and (iv).

2. The method of claim 1 , wherein the antibody of step (a) or step (i) is a monoclonal antibody that specifically binds to an epitope present in C3a/C3.

3. The method of claim 1 , wherein the sample comprises whole blood, plasma, or serum.

4. The method of claim 1 , wherein the sample comprises an agent being assessed for its ability to modulate complement activation.

5. The method of claim 1 , wherein the method comprises performing steps (a)-(e).

6. The method of claim 5 , wherein step (a) comprises capturing intact C3 using a monoclonal antibody that specifically binds to an epitope present in C3a/C3, and step (b) comprises detecting intact C3 using a polyclonal antibody that specifically binds to at least one epitope present in C3 and has a detectable label directly or indirectly linked thereto.

7. The method of claim 5 , wherein step (c) comprises capturing iC3b using a monoclonal antibody that specifically binds to a neoepitope of iC3b, and step (d) comprises detecting iC3b using a polyclonal antibody that specifically binds to at least one epitope present in iC3b, and has a detectable label directly or indirectly linked thereto.

8. The method of claim 1 , wherein the method comprises performing stens (i)-(v).

9. The method of claim 8 , wherein the capture antibody of step (i) comprises an antibody that specifically binds to at least one epitope present in C3d.

10. The method of claim 8 , wherein the capture antibody that binds to total C3 is a polyclonal antibody that specifically binds to at least one epitope present in C3d and intact C3 is detected using a monoclonal antibody that specifically binds to an epitope present in C3a and has a detectable label directly or indirectly linked thereto.

11. The method of claim 1 , wherein the method comprises determining the ratio of iC3b to intact C3, further comprising determining the concentration of total C3 in the sample.

12. The method of claim 1 , wherein the antibody used to capture intact C3 is a monoclonal antibody that binds to intact C3 and is specific for C3 as compared with iC3b or C3b.

13. The method of claim 12 , wherein the monoclonal antibody is anti-human C3a/C3 antibody HM2075 or an antibody that is at least as specific for intact C3 as compared with C3b, iC3b, C3c, and C3d as antibody clone 2898 (Hycult Biotechnology catalog number HM2075).

14. The method of claim 1 , wherein iC3b is captured or quantified using a monoclonal antibody that binds to a neoepitope of iC3b and is specific for iC3b as compared with C3b or C3.

15. The method of claim 14 , wherein the monoclonal antibody is A209 or an antibody that is at least as specific for iC3b as compared with C3b or C3 as monoclonal antibody A209 Quidel catalog number A209).

16. The method of claim 1 , wherein the antibody that captures intact C3 is immobilized on a support comprising a microwell plate or a plurality of particles.

17. The method of claim 1 , wherein the antibody that captures total C3 is immobilized on a support comprising a microwell plate or a plurality of particles.

18. A method of assessing complement activation in a sample, the method comprising steps of:
(a) capturing and detecting intact C3, wherein intact C3 is captured using an antibody that specifically binds to at least one epitope present in C3a/C3 but does not bind to C3 fragments other than C3a; and
(b) capturing and detecting iC3b, wherein iC3b is captured using an antibody that specifically binds to a neoepitope of iC3b, and
(c) calculating the ratio of iC3b to intact C3 using the results of (a) and (b), wherein the ratio of iC3b to intact C3 serves as an indicator of the extent of complement activation.

19. The method of claim 18 , wherein intact C3 is captured using a monoclonal antibody that specifically binds to an epitope present in C3a/C3 and is detected using a polyclonal antibody that specifically binds to at least one epitope present in C3 and has a detectable label directly or indirectly linked thereto.

20. The method of claim 18 , wherein iC3b is captured using a monoclonal antibody that specifically binds to a neoepitope of iC3b and is detected using a polyclonal antibody that specifically binds to at least one epitope of iC3b and has a detectable label directly or indirectly linked thereto.

Assignees

• Zhang Zhouning
• Francois Cedric
• Deschatelets Pascal
• Olson Paul
• Apellis Pharmaceuticals Inc

Inventors

• Zhang Zhouning
• Francois Cedric
• Deschatelets Pascal
• Olson Paul

Classifications

• C07K16/18 Primary

  against material from animals or humans · CPC title

• G01N2800/52

  Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis · CPC title

• G01N33/6893

  related to diseases not provided for elsewhere · CPC title

• G01N2800/164

  Retinal disorders, e.g. retinopathy · CPC title

• G01N2333/4716

  Complement proteins, e.g. anaphylatoxin, C3a, C5a · CPC title